Real-time in Vivo molecular detection of primary tumors and metastases with ratiometric activatable cell-penetrating peptides

Cancer Research

Volumn 73, Issue 2, 2013, Pages 855-864

  Savariar, Elamprakash N ^a   Felsen, Csilla N ^a   Nashi, Nadia ^a   Jiang, Tao ^a   Ellies, Lesley G ^a   Steinbach, Paul ^a   Tsien, Roger Y ^a   Nguyen, Quyen T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PENETRATING PEPTIDE; ELASTASE; FLUORESCENT DYE; GELATINASE A; GELATINASE B; RATIOMETRIC ACTIVATABLE CELL PENETRATING PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INVASION; CONTROLLED STUDY; FLUORESCENCE; IN VIVO STUDY; LIVER METASTASIS; LYMPH NODE METASTASIS; METASTASIS; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN CLEAVAGE; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY;

ANIMALS; CARBOCYANINES; CELL LINE, TUMOR; CELL-PENETRATING PEPTIDES; COMPUTER SYSTEMS; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMANS; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MICE, NUDE; SENSITIVITY AND SPECIFICITY; TRANSPLANTATION, HETEROLOGOUS;

EID: 84872560827     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-2969     Document Type: Article

References (29)

1. Bauvois B.Newfacets of matrix metalloproteinasesMMP-2andMMP- 9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim Biophys Acta 2012;1825: 29-36.
2. Uloza V, Liutkevicius V, Pangonyte D, Saferis V, Lesauskaite V. Expression of matrix metalloproteinases (MMP-2 and MMP-9) in recurrent respiratory papillomas and laryngeal carcinoma: clinical and morphological parallels. Eur Arch Otorhinolaryngol 2011;268: 871-8.
3. Wittekindt C, Jovanovic N, Guntinas-Lichius O. Expression of matrix metalloproteinase-9 (MMP-9) and blood vessel density in laryngeal squamous cell carcinomas. Acta Otolaryngol 2011;131: 101-6.
4. Liu WW, Zeng ZY, Wu QL, Hou JH, Chen YY. Overexpression of MMP- 2 in laryngeal squamous cell carcinoma: a potential indicator for poor prognosis. Otolaryngol Head Neck Surg 2005;132: 395-400.
5. Mallis A, Teymoortash A, Mastronikolis NS, Werner JA, Papadas TA. MMP-2 expression in 102 patients with glottic laryngeal cancer. Eur Arch Otorhinolaryngol 2012;269: 639-42.
6. Zhou CX, Gao Y, Johnson NW, Gao J. Immunoexpression of matrix metalloproteinase-2 and matrix metalloproteinase-9 in the metastasis of squamous cell carcinoma of the human tongue. Aust Dent J 2010;55: 385-9.
7. Olson ES, Aguilera TA, Jiang T, Ellies LG, Nguyen QT, Wong E, et al. In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer. Integr Biol 2009;1: 382-93.
8. Aguilera TA, Olson ES, Timmers MM, Jiang T, Tsien RY. Systemic in vivo distribution of activatable cell penetrating peptides is superior to cell penetrating peptides. Integr Biol 2009;1: 371-81.
9. Nguyen QT, Olson ES, Aguilera TA, Jiang T, Scadeng M, Ellies LG, et al. Surgery with molecular fluorescence imaging using activatable cellpenetrating peptides decreases residual cancer and improves survival. Proc Natl Acad Sci U S A 2010;107: 4317-22.
10. Tsien RY, Harootunian AT. Practical design criteria for a dynamic ratio imaging system. Cell Calcium 1990;11: 93-109.
11. Hoshida T, Isaka N, Hagendoorn J, di Tomaso E, Chen YL, Pytowski B, et al. Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: Therapeutic implications. Cancer Res 2006;66: 8065-75.
12. Tsien RY. Monitoring cell calcium. In:Carafoli E, Klee C, editors. Calcium as a cellular regulator. New York: Oxford University Press; 1999. p. 28-54.
13. Tsien RY. Indicators based on fluorescence resonance energy transfer. In:Yuste R, Konnerth A, editors. Imaging in neuroscience and development. Cold Spring Harbor, China: Cold Spring Harbor Laboratory Press; 2005. p. 549-56.
14. Levenson R, Beechem J, McNamara G. Spectral imaging in preclinical research and clinical pathology. Anal Cell Pathol (Amst) 2012;35: 339-61.
15. Tseng WW, Winer D, Kenkel JA, Choi O, Shain AH, Pollack JR, et al. Development of an orthotopic model of invasive pancreatic cancer in an immunocompetent murine host. Clin Cancer Res 2010;16: 3684-95.
16. van Duijnhoven SM, Robillard MS, Nicolay K, Grull H. Tumor targeting of MMP-2/9 activatable cell-penetrating imaging probes is caused by tumor-independent activation. J Nucl Med 2011;52: 279-86.
17. Whitney M, Crisp JL, Olson ES, Aguilera TA, Gross LA, Ellies LG, et al. Parallel in vivo and in vitro selection using phage display identifies protease dependent tumor targeting peptides. J Biol Chem 2010;285: 22532-41.
18. Olson ES, Jiang T, Aguilera TA, Nguyen QT, Ellies LG, Scadeng M, et al. Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence andMRimaging of proteases. Proc Natl Acad Sci U S A 2010;107: 4311-6.
19. Bremer C, Bredow S, Mahmood U, Weissleder R, Tung CH. Optical imaging of matrix metalloproteinase-2 activity in tumors: feasibility study in a mouse model. Radiology 2001;221: 523-9.
20. Bremer C, Tung CH, Weissleder R. In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med 2001;7: 743-8.
21. Jiang T, Olson ES, Nguyen QT, Roy M, Jennings PA, Tsien RY. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci USA 2004;101: 17867-72.
22. Levi J, Kothapalli SR,MaTJ, Hartman K, Khuri-Yakub BT, Gambhir SS. Design, synthesis, and imaging of an activatable photoacoustic probe. J Am Chem Soc 2010;132: 11264-9.
23. Zhu L, Xie J, Swierczewska M, Zhang F, Quan Q, Ma Y, et al. Real-time video imaging of protease expression in vivo. Theranostics 2011;1: 18-27.
24. Linder KE, Metcalfe E, Nanjappan P, Arunachalam T, Ramos K, Skedzielewski TM, et al. Synthesis, in vitro evaluation, and in vivo metabolism of fluor/quencher compounds containing IRDye 800CW and Black Hole Quencher-3 (BHQ-3). Bioconjugate Chem 2011;22: 1287-97.
25. Chen J, Liu TW, Lo PC, Wilson BC, Zheng G. "Zipper" molecular beacons: a generalized strategy to optimize the performance of activatable protease probes. Bioconjugate Chem 2009;20: 1836-42.
26. Technical Data Sheet, Fluorescent Imaging Agent MMPSense 680. Available from: www.perkinelmer.com/CMSResources/Images/44-73969TCHNEV10126-MMPSense680- TD.pdf.
27. Whitney M, Savariar EN, Friedman B, Levin RA, Crisp JL, Glasgow H, et al. Ratiometric Activatable Cell-Penetrating Peptides Provide Rapid In vivo Readout of Thrombin Activation. Angew Chem Int Ed Engl. 2011: doi 10.1002/anie. 201205721 (epub ahead of print).
28. van Dam GM, Themelis G, Crane LM, Harlaar NJ, Pleijhuis RG, Kelder W, et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results. Nat Med 2011;17: 1315-9.
29. Hutteman M, van der Vorst JR, Gaarenstroom KN, Peters AA, Mieog JS, Schaafsma BE, et al. Optimization of near-infrared fluorescent sentinel lymph node mapping for vulvar cancer. Am J Obstet Gynecol 2012;206: 89 e1-5.